The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic

James F Meschia1, Kevin M Barrett2, Robert D Brown2

  • 1From the Department of Neurology (J.F.M., K.M.B., T.G.B.), Mayo Clinic, Jacksonville, FL; Department of Neurology (R.D.B.), Mayo Clinic, Rochester, MN; Department of Neurology (T.N.T., J.H.V.), Medical University of South Carolina, Charleston; Department of Epidemiology (V.J.H.) and Department of Biostatistics (G.H.), University of Alabama at Birmingham; Department of Surgery (B.K.L.), University of Maryland, College Park. meschia.james@mayo.edu.

Neurology
|May 3, 2020
PubMed

Insights

The coronavirus disease 2019 pandemic impacted a major stroke prevention trial, necessitating changes in patient enrollment and follow-up. Strategies were implemented to protect patients and ensure trial objectives were met despite disruptions.

Area of Science:

  • Neurology
  • Clinical Trials
  • Epidemiology

Background:

  • The coronavirus disease 2019 (COVID-19) pandemic caused widespread disruption to global health systems and research.
  • Clinical trials faced unprecedented challenges, including operational adjustments and patient safety concerns.

Purpose of the Study:

  • To describe the impact of the COVID-19 pandemic on the National Institute of Neurological Disorders and Stroke (NINDS) Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial.
  • To outline the mitigation strategies implemented to ensure patient safety and trial continuity.

Main Methods:

  • The study details the immediate effects of the pandemic on trial operations, including suspension of new patient enrollment.
  • Methods involved transitioning patient follow-up from in-person visits to telephone contacts.
  • Ethical considerations for patient protection were paramount in adapting trial procedures.

Main Results:

  • The trial experienced significant operational changes due to the pandemic, including a halt in new participant recruitment.
  • Patient follow-up was successfully adapted to a remote, telephone-based model.
  • Mitigation strategies were developed to address pandemic-related challenges.

Conclusions:

  • The pandemic necessitated rapid adaptation of clinical trial protocols to ensure patient safety and data integrity.
  • The experience highlights the need for flexible and resilient trial designs in public health emergencies.
  • Successful mitigation allowed the trial to continue pursuing its stroke prevention objectives.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
910
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
190
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
291